Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study
Cynthia Levy(University of Miami), Alexandra Steinberg(CymaBay Therapeutics (United States)), Elena Muslimova, Wendy Chen(The University of Texas MD Anderson Cancer Center), Marlyn J. Mayo(The University of Texas Southwestern Medical Center), Mitchell L. Shiffman(Bon Secours Health System), Klara Dickinson, Christoph Berg(University College Hospital), John M. Vierling, Sandrin C. Bergheanu, Aliya Gulamhusein, Aparna Goel(Stanford University), Charles Landis(Albert Einstein College of Medicine), Gideon M. Hirschfield(University of Birmingham), Christopher L. Bowlus(University of Padua), Richard Aspinall(Queen Alexandra Hospital), Adam Peyton, Tarek Hassanein, Charles A. McWherter(CymaBay Therapeutics (United States)), Stuart C. Gordon(Henry Ford Health System), Frances Seput-Dingle, Marcus-Alexander Woerns, Pol Boudes(CymaBay Therapeutics (United States)), Paul J. Thuluvath(Inova Fairfax Hospital), Palak Trivedi, Lily Mao, David C. Sheridan, Lynsey Corless(University of Hull), Peter Buggisch(Universität Hamburg), Andreas E. Kremer(Friedrich-Alexander-Universität Erlangen-Nürnberg), Mark G. Swain(University of Calgary), Joseph A. Odin(Icahn School of Medicine at Mount Sinai), Carmen Stanca, David I. Bernstein(Cincinnati Children's Hospital Medical Center), Stephen A. Harrison(Louisiana State University), Yu Li(Boston University), Mónika Varga(CymaBay Therapeutics (United States)), Yun‐Jung Choi(CymaBay Therapeutics (United States)), David Jones(University of Padua), Brian B. Borg(National Institute of Diabetes and Digestive and Kidney Diseases), Guy Neff, Bruce R. Bacon(Saint Louis University), Yvonne Döerffel(Charité - Universitätsmedizin Berlin), Ke Yang(Chinese Academy of Sciences), Galambos Michael, Douglas Thorburn(Royal Free London NHS Foundation Trust)
Cited by 10
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k